D. Lansing Taylor is the Director at the University of Pittsburgh Drug Discovery Institute (UPDDI), Pennsylvania and a faculty member in the Department of Computational and Systems Biology.[2]
D. Lansing (Lans) Taylor | |
|---|---|
| Alma mater |
|
| Awards |
|
| Scientific career | |
| Institutions | University of Pittsburgh |
| Website | |
Early life and education
editLansing Taylor was born in Baltimore, Maryland. He received his B.S. in zoology from the University of Maryland,[3] followed by his Ph.D. in the field of cell biology from the State University of New York at Albany.[4] He spent a postdoctoral fellowship at the Marine Biological Laboratory (MBL) in Woods Hole in the field of cellular biophysics.[5]
Research and career
editLansing Taylor originally did research on the cellular and molecular mechanisms of Amoeboid movements at Harvard University as an assistant and associate professor.[6] He moved to Carnegie Mellon University (CMU) as a professor to direct the Center for Fluorescence Research where he led the program to develop fluorescence-based biosensors of cellular physiology and light microscope imaging systems for various applications in basic biomedical research.[7][8] During this time he co-founded Biological Detection Systems to commercialize fluorescence-based reagents and research imaging platforms, later purchased by Amersham, now GE Life Sciences. Lans left CMU to found Cellomics and created High Content Screening (HCS) for large-scale phenotypic screening for drug discovery and development which later became part of ThermoFisher.[9] Cellumen was the next company founded by Lans to apply systems cell biology to both drug safety testing (now part of Cyprotex) and cancer diagnostics.[10][11][12][13] The cancer diagnostics unit was spun off as Cernostics and they created a test for Barrett's Esophagus. He returned to academia as the Director of the UPDDI. His current research interests include the development and application of human microphysiology systems as more advanced experimental models for drug discovery and development, the application of quantitative systems pharmacology (QSP) for a new paradigm in drug discovery and computational and systems pathology to predict therapeutic strategies for a variety of diseases.[14] He is the co-founder and Chairman of SpIntellx, a computational and systems pathology company with focus on spatial analytics and explainable AI (xAI).[15]
Awards and honors
editD. Lansing Taylor received the Society for Biomolecular Sciences (SBS) Accomplishment Award for the development of High-Content Screening (HCS).[16][17] His additional awards include the Smithsonian Award for developing live cell imaging technologies and the Mack Fulwyler Award from the International Society for Advancement of Cytometry (ISAC) for outstanding contributions to the field of cytometry.[18] Lans is a Fellow of the American Institute for Medical and Biomedical Engineering.[19] Honors include receiving the National Science Foundation Pioneer Award for recognition of the vision, leadership and entrepreneurial spirit for the Science and Technology Centers and the Ernst & Young Entrepreneur of the Year in Pennsylvania for Cellomics.[20]
Grants
edit- D. Lansing Taylor research on Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets was funded by the National Institute of Health (NIH) agency and the project started on 20 September 2018 and it will end on 31 July 2023.[21]
- D. Lansing Taylor research on Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma was funded by the National Institute of Health (NIH) agency and the project started on 1 August 2018 and it will end on 31 July 2023.[22]
- D. Lansing Taylor research on Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD) was funded by the National Institute of Health (NIH) agency and the project started on 1 August 2018 and it will end on 30 April 2022.[23]
Patents
editDr. Taylor has obtained more than 29 patents for his inventions. His patents include;
- Standing wave luminescence microscopy, (1986).[24]
- System for Cell-based screening, (1999).[25]
- Field synthesis and optical subsectioning for standing wave microscopy, (2000).[26]
- Miniaturized cell array methods and apparatus for cell-based screening, (2000).[27]
- Method for automated tissue analysis, (2012).[28]
References
edit- ^ "Lansing". cen.acs.org.
- ^ "D. Lansing Taylor | Computational & Systems Biology". Retrieved 25 August 2019.
- ^ "Drug Discovery Institute - D. Lansing Taylor". www.upddi.pitt.edu. Retrieved 25 August 2019.
- ^ "D. Lansing Taylor | Computational & Systems Biology". Retrieved 25 August 2019.
- ^ Taylor, D. L. (1 August 2003). "An Interview with D. Lansing Taylor, Ph.D., Chief Executive Officer, Cellomics, Inc". ASSAY and Drug Development Technologies. 1 (4): 501–505. doi:10.1089/154065803322302754. ISSN 1540-658X. PMID 15090246.
- ^ Taylor, D. Lansing; Condeelis, Johns S. (1 January 1979), Bourne, G. H.; Danielli, J. F. (eds.), Cytoplasmic Structure and Contractility in Amoeboid Cells, International Review of Cytology, vol. 56, Academic Press, pp. 57–144, doi:10.1016/s0074-7696(08)61821-5, ISBN 9780123643568, PMID 37189
- ^ "Faculty List". Retrieved 25 August 2019.
- ^ "Fluorescence Microscopy of Living Cells in Culture, Part A, Volume 29 - 1st Edition". www.elsevier.com. Retrieved 25 August 2019.
- ^ Taylor, D. Lansing, ed. (2006). High Content Screening. Methods in Molecular Biology. Humana Press. ISBN 9781588297310.
- ^ "Cellumen Spins Off Personalized Medicine Unit as Cernostics Pathology, Inc". www.businesswire.com. 16 July 2008. Retrieved 26 August 2019.
- ^ "Cellumen to Collaborate with the NCTR of the FDA to Apply Cellular Systems Biology to Predictive Toxicology". Drug Discovery from Technology Networks. Retrieved 26 August 2019.
- ^ "Cellumen Inc". BioCentury – BCIQ. Retrieved 26 August 2019.
- ^ "Cellumen Creates New Firm from Its Personalized Medicine Unit". GEN - Genetic Engineering and Biotechnology News. 17 July 2008. Retrieved 26 August 2019.
- ^ "QuantitativeSystemsPharmacologyandtheBridgefrominvitrotoinvivoToxicologyandDiseaseModeling" (PDF).
- ^ "SpIntellx". SpIntellx. Retrieved 6 May 2021.
- ^ "D. Lansing Taylor Receives 2007 SBS Accomplishment Award | Chemical & Engineering News". cen.acs.org. Retrieved 26 August 2019.
- ^ SelectScience. "D. Lansing Taylor Receives the 2007 SBS Accomplishment Award | SelectScience". www.selectscience.net. Retrieved 26 August 2019.
- ^ "About". MBIC. 18 February 2015. Retrieved 26 August 2019.
- ^ "D. Lansing Taylor, Ph.D. COF-0987 - AIMBE". Retrieved 26 August 2019.
- ^ "Advances and New Approaches in Imaging Technology: Expanding the Reach of High-Content Analysis". Science | AAAS. 25 January 2017. Retrieved 26 August 2019.
- ^ Taylor, D. "Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets". Retrieved 6 May 2021.
- ^ Murphy, William; Taylor, D.; Wikswo, John. "Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma". Retrieved 6 May 2021.
- ^ Taylor, D. "Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)". Retrieved 6 May 2021.
- ^ US 4621911, Lanni, Frederick; Taylor, D. Lansing & Waggoner, Alan S., "Standing wave luminescence microscopy", published 1986-11-11, assigned to Carnegie-Mellon University
- ^ US 5989835, Dunlay, R. Terry & Taylor, D. Lansing, "System for cell-based screening", published 1999-11-23, assigned to Cellomics Inc.
- ^ US 6055097, Lanni, Frederick; Taylor, D. Lansing & Bailey, Brent, "Field synthesis and optical subsectioning for standing wave microscopy", published 2000-04-25, assigned to Carnegie-Mellon University
- ^ US 6103479, Taylor, D. Lansing, "Miniaturized cell array methods and apparatus for cell-based screening", published 2000-08-15, assigned to Cellomics Inc.
- ^ US 8114615, Gough, Albert H.; Giuliano, Kenneth A. & Taylor, D. Lansing, "Method for automated tissue analysis", published 2012-02-14, assigned to Cernostics Inc.